Considering the time and costs associated with the discovery of novel therapeutic agents, and the well-documented protective role of S1R, this review aims to highlight the effectiveness of available drugs that target S1R as a potential treatment for neurodegenerative diseases—particularly those lacking viable therapies. This evidence concerns the gene TMBIM4 and neurodegenerative disease.